Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/1999
10/28/1999CA2328430A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999CA2328331A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
10/28/1999CA2328264A1 Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
10/28/1999CA2323571A1 Novel human k+ ion channel and therapeutic applications thereof
10/28/1999CA2322759A1 Novel diphenyl-substituted 6-ring-heterocycles, methods for producing them and their use as medicaments
10/27/1999EP0952218A2 Single chain, multiple antigen-binding molecule, its preparation and use
10/27/1999EP0952159A2 Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents
10/27/1999EP0952154A2 N-acyl and N-aroyl aralkyl amides
10/27/1999EP0951842A2 Infant formula
10/27/1999EP0951556A2 Disease associated protein tyrosine phosphatases
10/27/1999EP0951543A1 Human glycine transporter
10/27/1999EP0951537A1 Recombinant collagen and derived proteins produced by plants, methods for obtaining them and uses
10/27/1999EP0951536A1 Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
10/27/1999EP0951472A1 Peptide compositions with growth factor-like activity
10/27/1999EP0951467A1 SUBSTITUTED NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF p38 PROTEIN KINASE
10/27/1999EP0951466A2 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
10/27/1999EP0951465A1 Alpha-amino acid amides, preparation thereof and the therapeutical use thereof
10/27/1999EP0951464A1 N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
10/27/1999EP0951293A1 Method for treating alzheimer's disease
10/27/1999EP0951284A1 Phenylethylamine derivatives
10/27/1999EP0617616B1 Potentiation of nmda antagonists
10/27/1999EP0584088B1 Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
10/27/1999CN1233249A Spiro(cyclopent [B] indole-piperidines) and N-phenyl-hydrazon intermediates for their preparation, both being acetylcholinesterase and MAO inhibitors
10/27/1999CN1233248A 1H-pyrido [3,4-b] indole-4-carboxamide derivatives, preparation and application thereof in therapeutics
10/27/1999CN1233245A Oxadiazoles, processes for their preparation and their use as medicaments
10/27/1999CN1233243A Crystalline form of 4-[5-methyl-3-phenylisoxazol)-4-yl] benzenesulfonamide
10/27/1999CN1233238A Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists
10/27/1999CN1233173A Therapeutic methods and compositions involving isoflavones
10/27/1999CN1233169A Process for the manufacture of a pulverous preparation
10/27/1999CN1232675A Non-toxic cotton seed extractions and their extraction process, medicinal composite and use as medicine for nervous system
10/27/1999CN1045964C Heterocyclic compounds and their preparation and use
10/27/1999CN1045957C Tricyclic benzazepine, their application and preparation
10/27/1999CA2269995A1 Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects
10/26/1999US5973201 Phenylacetamide derivatives
10/26/1999US5973152 Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
10/26/1999US5973150 Pharmacologically active enantiomers
10/26/1999US5973111 Novel compounds that are capable of binding to the active site of interleukin-1b-converting enzyme (ice) and inhibiting activity of that enzyme; administering to treat inflammatory, autoimmune, and neurodegenerative diseases
10/26/1999US5973006 Nervous system disorders; alzheimer's disease; huntington disease; parkinson's disease
10/26/1999US5972964 Aminomethylindans, -benzofurans and -benzothiophenes
10/26/1999US5972961 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
10/26/1999US5972951 Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists
10/26/1999US5972946 Nervous system disorders; psychological disorders
10/26/1999US5972940 Arginine analogues having nitric oxide synthase inhibitor activity
10/26/1999US5972937 Treating central nervous system disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks
10/26/1999US5972936 Benzofuran carboxamides and their therapeutic use
10/26/1999US5972935 Psychological disordrs, nervous system disorders, parkinson's disorder
10/26/1999US5972925 1-(3-(2-chloro-12h-dibenzo(d,g)(1,3,6)dioxazocin-12-yl)-1-prop yl)-3-piperidinecarboxylic acid, for example; treating neurogenic pain (in which c-fibers play a role) or inflammation such as migraine or diabetic neuropathy
10/26/1999US5972924 Administering cyclosporin a to a human whose blood-brain barrier has been opened, or where cyclosporin a is able to cross the blood brain barrier
10/26/1999US5972923 Methods and compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
10/26/1999US5972899 Apoptosis induced by Shigella IpaB
10/26/1999US5972894 Peptides having potassium channel opener activity
10/26/1999US5972652 Polynucleotides encoding secreted proteins
10/26/1999US5972651 Polynucleotides and polypeptides of the fifty-four homologue family, (ffh); vectors and transformed host cells; ffh are components of protein secretory apparatus and their inhibition of function is deleterious to bacteria cells
10/26/1999US5972606 A polypeptide; treating osteoporosis, eating disorders, brain disorders, adult respiratory disease syndrome, huntington'sdisease, ulcers, cardiovascular disorders, parkinson's disease;
10/26/1999CA2183320C Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
10/26/1999CA2177576C Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
10/26/1999CA2132993C Physiologically active substance
10/21/1999WO1999053055A2 Therapeutic agent for ngf
10/21/1999WO1999053036A2 Ste20-related protein kinases
10/21/1999WO1999053028A1 Pns cell lines and methods of use therefor
10/21/1999WO1999052935A1 Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepin- 1-carboxamide
10/21/1999WO1999052927A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999WO1999052903A1 Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
10/21/1999WO1999052902A1 Method for drying anhydrous paroxetine hydrochloride
10/21/1999WO1999052901A1 Paroxetine maleate
10/21/1999WO1999052898A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052870A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
10/21/1999WO1999052868A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052538A1 Composition containing a herbal medicinal substance and a pharmaceutical drug
10/21/1999WO1999052536A1 Use of at least a plant extract of the compositae family, such as the genus bellis
10/21/1999WO1999052531A1 New treatments for nervous disorders
10/21/1999WO1999052525A1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/21/1999WO1999052524A1 Use of cannabinoids as anti-inflammatory agents
10/21/1999WO1999052519A2 Methods for treating neuropsychiatric disorders
10/21/1999WO1999052518A2 New treatments for nervous disorders
10/21/1999WO1999052517A2 Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps
10/21/1999WO1999052516A2 Acylpeptide protease inhibitors to enhance cognitive function
10/21/1999WO1999052514A2 Pharmaceutical composition and combination preparation for immunosuppressive therapy
10/21/1999WO1999052493A2 Compounds that inhibit the binding of integrins to their receptors
10/21/1999WO1999046254A3 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis
10/21/1999WO1999046245A3 PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
10/21/1999WO1999043676A3 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
10/21/1999WO1999039712A9 Substituted semicarbazides and the use thereof
10/21/1999WO1999037623A3 Sulphonamide derivatives for treatment of cns disorders
10/21/1999WO1999032643A3 Mood disorder gene
10/21/1999WO1999030738A3 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/21/1999WO1999026927A3 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
10/21/1999WO1998041625A8 Variants of ciliary neurotrophic factor with enhanced receptor selectivity and method for their selection
10/21/1999DE19818614A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817461A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817459A1 New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19816882A1 Use of known and new triazolone derivatives as medicaments, especially for treatment of neurodegenerative disorders and cerebral ischemia
10/21/1999DE19816880A1 New diaryl substituted heterocyclic compounds are AMPA receptor antagonists useful in treatment of neurodegenerative disorders and cerebral ischemia
10/21/1999DE19816857A1 Novel adenosine antagonists useful in treatment of e.g. neurodegenerative, pulmonary, renal and cardiovascular disorders
10/21/1999DE19806581A1 Sequenzen eines Ih-Ionenkanals und deren Verwendung Sequences of Ih ion channel and their use
10/21/1999CA2634698A1 New treatments for nervous disorders
1 ... 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 ... 1833